Skip to main content
logo
Catalyst Pharmaceuticals, Inc. (CPRX)
Jul 15, 2026 - CPRX was delisted (reason: acquired by Angelini Pharma)
31.49
0.00 (0.00%)
Inactive · Last trade price on Jul 15, 2026

Catalyst Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
221.32214.33163.8971.4183.0839.48
Depreciation & Amortization
38.1937.8737.7732.881.240.19
Asset Writedown & Restructuring Costs
---81.51--
Loss (Gain) From Sale of Investments
-3.08-0.97-5.08-3.020.76-
Stock-Based Compensation
25.1924.7822.2514.257.916.07
Other Operating Activities
-6.53-6.44-9.95-16.119.339.6
Change in Accounts Receivable
-59.57-61-11.96-43.08-3.82-0.63
Change in Inventory
-15.62-18.09-3.9-4.741.07-3.22
Change in Accounts Payable
-4.05-5.391.810.821.21-1.49
Change in Other Net Operating Assets
12.3523.5944.98-0.3315.2810.36
Operating Cash Flow
208.21208.67239.81143.6116.0560.37
Operating Cash Flow Growth
-22.29%-12.98%67.00%23.74%92.22%34.06%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.09-0.06-0.56-198.52-10.03-1.02
Sale (Purchase) of Intangibles
----81.51--
Investment in Securities
----13.4719.24-10
Investing Cash Flow
-0.09-0.06-0.56-293.59.21-11.02

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
13.1814.67154.522.799.574.1
Repurchase of Common Stock
-41.31-27.07-0.67-0.98-7.14-12.24
Other Financing Activities
-4.8-4.59-13.18-12.67-0.74-
Financing Cash Flow
-32.93-16.99140.67-10.861.69-8.14

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
175.2191.62379.92-160.76126.9541.21

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
208.13208.61239.25-54.92106.0259.35
Free Cash Flow Growth
-22.21%-12.81%--78.63%31.82%
Free Cash Flow Margin
34.87%35.42%48.66%-13.79%49.49%42.14%
Free Cash Flow Per Share
1.641.641.92-0.480.950.55
Levered Free Cash Flow
171.81171.34201.64-219.4989.6942.14
Unlevered Free Cash Flow
171.81171.34201.64-219.4989.6942.14

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.50.471.40.71--
Cash Income Tax Paid
73.1971.9968.4550.467.673
Change in Working Capital
-66.88-60.930.91-37.3213.735.02
SEC Filings: 10-K · 10-Q